| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175528-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $189.90 | |
| Ab175528-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $919.90 | |
| Ab175528-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,299.90 | |
| Ab175528-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $3,679.90 |
Purity>90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAE)
| Product Name | Enfortumab vedotin-ejfv (anti-Nectin-4) - Primary antibody, specific to NECTIN, >90% (SDS-PAGE&SEC), high purity, Human IgG1 |
|---|---|
| Synonyms | DKFZp686K05193 antibody | EDSS1 antibody | Ig superfamily receptor LNIR antibody | Nectin 4 antibody | Nectin-4 antibody | poliovirus receptor-related 4 antibody | Processed poliovirus receptor-related protein 4 antibody | PRR4 antibody | pvrl4 antibody | |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥90%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | NECTIN |
| Conjugation | MC-VC-PAB-MMAE |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | ANTIBODY |
| Mechanism of action | Antibody of nectin cell adhesion molecule 4 |
| Product Description |
Enfortumab vedotin-ejfv (anti-Nectin-4) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv (anti-Nectin-4) has the potential for use in research of urothelial carcinoma. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 143.9 kDa |
| Purification Method | Protein A purified |
| Purity | >90% (SDS-PAGE&SEC) |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1346452-25-2 |
Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) - ELISA
Immobilized Recombinant Human Nectin-4 protein (rp183631) at 1.0 μg/mL can bind Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) with the EC50 of 17.59 ng/mL.
Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) - SEC
The purity of Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0607451 | Certificate of Analysis | Jun 28, 2024 | Ab175528 |
| ZJ24F0607450 | Certificate of Analysis | Jun 28, 2024 | Ab175528 |
| ZJ24F0607449 | Certificate of Analysis | Jun 28, 2024 | Ab175528 |
| 1. Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR et al.. (2016) Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.. Cancer Res, 76 (10): (3003-13). [PMID:27013195] [10.1021/op500134e] |
| 2. McGregor BA, Sonpavde G. (2019) Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.. Expert Opin Investig Drugs, 28 (10): (821-826). [PMID:31526130] [10.1021/op500134e] |
| 3. Hanna KS. (2020) Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.. Drugs, 80 (1): (1-7). [PMID:31823332] [10.1021/op500134e] |
